Metformin and cardiorenal outcomes in diabetes: A reappraisal

Author:

Petrie John R.1,Rossing Peter R.23,Campbell Ian W.4

Affiliation:

1. Institute of Cardiovascular & Medical Sciences University of Glasgow Glasgow UK

2. Steno Diabetes Center Copenhagen Denmark

3. University of Copenhagen Copenhagen Denmark

4. School of Medicine University of St. Andrews St. Andrews UK

Funder

Merck

European Association for the Study of Diabetes

Food and Drug Administration

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference81 articles.

1. Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes

2. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

3. PratleyRE HandelsmanY. Should metformin be the first‐line therapy choice in type 2 diabetes treatment? Endocrine Today.https://www.healio.com/endocrinology/diabetes/news/print/endocrine-today/%7B0d91ed6f-9d3e-4cbd-908d-5d4802b65a24%7D/should-metformin-be-the-first-line-therapy-choice-in-type-2-diabetes-treatment. Accessed October 2019.

Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Diabetes-Induced Cardiomyopathy: Updates in Epidemiology, Prevention, and Management;Etiology, Prevention and Management of Cardiomyopathy [Working Title];2024-09-08

2. Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin;Diabetes, Obesity and Metabolism;2024-07-11

3. Metformin beyond type 2 diabetes: Emerging and potential new indications;Diabetes, Obesity and Metabolism;2024-07-04

4. Metformin: Therapeutic profile in the treatment of type 2 diabetes;Diabetes, Obesity and Metabolism;2024-05-24

5. Metformin: Past, Present, and Future;Current Diabetes Reports;2024-04-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3